SB 239063|SB-239063|Purchase|DC CHEM

Cas No.:	193551-21-2
Chemical Name:	SB-239063; SB239063
Synonyms:	SB-239063; SB239063
SMILES:	COC1=NC=CC(C2=C(N=CN2[C@H]3CC[C@H](O)CC3)C4=CC=C(F)C=C4)=N1
Formula:	C₂₀H₂₁FN₄O₂
M.Wt:	368.4
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. IC50 value: 44 nM ( p38α)Target: p38 MAPKSB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.

COA

MSDS

Cat. No.	Product name	Field of application
DC7028	SB242235	SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM.
DC9300	TA-02	TA-02 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction. Potently inhibits p38α, CK1δ and CK1ε (IC50 values are 20, 32 and 32 nM respectively).
DC7946	SKF-86002	SKF-86002 is a potent inhibitor of p38 MAP kinase wit IC50 of 0.5-1 uM; inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 μM).
DC1004	SB-203580	SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM and blocks PKB phosphorylation with IC50 of 3-5 μM.
DC7807	SB 239063	SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580.
DC2097	SB202190	SB 202190 is a pyridinyl imidazole that inhibits the p38 pathway.
DC5095	PD169316	PD169316 is a potent and selective p38 MAP kinase inhibitor
DC9681	Pamapimod（R-1503）	Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.
DC8630	Ralimetinib 2MsOH(LY2228820)	LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively).
DC7836	Doramapimod (BIRB-796)	BIRB 796 (Doramapimod) is a highly selective p38α MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKCα/β/γ.